AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12037739 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intravenous glucose tolerance test (IVGTT)
Number of subjects: 6
Study 12037739 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose effectiveness (Sg)
Number of subjects: 6
Study 12037739 — intervention group
Group type: COMPARATOR
Intervention: Insulin sensitivity index (SI)
Number of subjects: 6
Study 12037739 — intervention group
Group type: COMPARATOR
Intervention: Insulin secretion (AIR(Glucose))
Number of subjects: 6
Study 12037739 — intervention group
Group type: COMPARATOR
Intervention: Fasting insulin
Number of subjects: 6
Study 10562483 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.02 mg/kg)
Number of subjects: 113
Study 10562483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline solution)
Number of subjects: 113
Study 10562483 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (in cardio‐inhibitory form)
Number of subjects: 113
Study 10562483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in cardio‐inhibitory form)
Number of subjects: 113
Study 10562483 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (in vasodepressor form)
Number of subjects: 113
Study 10562483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in vasodepressor form)
Number of subjects: 113
Study 8539548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg body weight per day over 2 consecutive days
Number of subjects: 9
Study 8539548 — intervention group
Group type: COMPARATOR
Intervention: Observation (no specific therapy)
Number of subjects: 9
Study 2096044 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 272
Study 2096044 — intervention group
Group type: COMPARATOR
Intervention: Hand sewn anastomosis
Number of subjects: 272
Study 338254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 20 mg piribedil tablets
Number of subjects: 10
Study 338254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 50 mg piribedil in a sustained-release tablet formulation
Number of subjects: 10
Study 338254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31663972 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 50300
Study 31343603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Shower (CWS) - 15 minutes, 15° C water shower
Number of subjects: 9
Study 31343603 — intervention group
Group type: COMPARATOR
Intervention: Control (SIT25) - 15 minutes passive recovery in 25° C room
Number of subjects: 9
Study 28217989 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous radiofrequency ablation (RFA)
Number of subjects: 500
Study 28217989 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 500
Study 28217989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided foam sclerotherapy (UGFS)
Number of subjects: 500
Study 28217989 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation and stripping (HL/S)
Number of subjects: 500
Study 25419615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/d
Number of subjects: 7469
Study 25419615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg/d
Number of subjects: 7469
Study 25419615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7469
Study 25419615 — intervention group
Group type: COMPARATOR
Intervention: Other disease-modifying treatments
Number of subjects: 7469
Study 25419615 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for relapses
Number of subjects: 7469
Study 25419615 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmarketing setting (Fingolimod 0.5 mg/d)
Number of subjects: 7469
Study 23797054 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurement (HBPM) by a trained relative
Number of subjects: 60
Study 21784757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 80
Study 21784757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19699855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered disease-management intervention combining patient self-management support and provider medication management
Number of subjects: 400
Study 19699855 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 400
Study 19699855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered disease-management intervention
Number of subjects: 400
Study 16679713 — intervention group
Group type: EXPERIMENTAL
Intervention: Small container
Number of subjects: 20
Study 16679713 — intervention group
Group type: COMPARATOR
Intervention: Large container
Number of subjects: 20
Study 15326133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean height contour measurements along the disc margin
Number of subjects: 230
Study 15326133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean height contour measurements in the parapapillary region
Number of subjects: 230
Study 15326133 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM Gaussian techniques with regional parameters
Number of subjects: 230
Study 15326133 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM Gaussian techniques with global parameters
Number of subjects: 230
Study 15326133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean height contour measures along the disc margin
Number of subjects: 230
Study 15326133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean height contour measures in the parapapillary region
Number of subjects: 230
Study 15326133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation and optimization techniques
Number of subjects: 230
Study 11502793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment
Number of subjects: 0
Study 11502793 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondiabetic obese women)
Number of subjects: 0
Study 8998091 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-quinidine (VER-Q)
Number of subjects: 44
Study 8998091 — intervention group
Group type: COMPARATOR
Intervention: Digoxin-quinidine (DIG-Q)
Number of subjects: 44
Study 8438824 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated incision device
Number of subjects: 40
Study 8438824 — intervention group
Group type: COMPARATOR
Intervention: Lancet puncture device
Number of subjects: 40
Study 3553493 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 626
Study 3553493 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 626
Study 3553493 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 626
Study 3553493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (added to treatment)
Number of subjects: 626
Study 30772211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Bifocal
Number of subjects: 44
Study 30772211 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-near multifocal lenses
Number of subjects: 44
Study 30772211 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-distance multifocal lenses
Number of subjects: 44
Study 30772211 — intervention group
Group type: COMPARATOR
Intervention: Single vision control (Air Optix Aqua)
Number of subjects: 44
Study 30257696 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride and fluoride varnish
Number of subjects: 0
Study 30257696 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer therapeutic sealants and fluoride varnish
Number of subjects: 0
Study 30257696 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by nurses
Number of subjects: 0
Study 30257696 — intervention group
Group type: COMPARATOR
Intervention: Care provided by dental hygienists
Number of subjects: 0
Study 30257696 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention measures
Number of subjects: 0
Study 27869225 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS) for 30 minutes twice with a 4-hour interval
Number of subjects: 30
Study 27869225 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS) for 3 hours
Number of subjects: 30
Study 27869225 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 30
Study 24464974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin 300 mg/4 ml (TNS4)
Number of subjects: 321
Study 24464974 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized tobramycin 300 mg/5 ml (TNS5)
Number of subjects: 321
Study 24341502 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended-learning approach (BL)
Number of subjects: 61
Study 24341502 — intervention group
Group type: COMPARATOR
Intervention: Didactic approach (DID)
Number of subjects: 61
Study 20203108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use intervention
Number of subjects: 5603
Study 20203108 — intervention group
Group type: COMPARATOR
Intervention: Health education control intervention
Number of subjects: 5603
Study 17765380 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200-300 mg/day depending on weight)
Number of subjects: 60
Study 17765380 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (20-30 mg/day depending on weight)
Number of subjects: 60
Study 15754390 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids at 60 mg or more daily with or without anti-viral drugs within 10 days after diagnosis (early high-dose group)
Number of subjects: 22
Study 15754390 — intervention group
Group type: COMPARATOR
Intervention: Non-early high-dose group (treated more than 10 days or untreated with corticosteroids)
Number of subjects: 22
Study 12760310 — intervention group
Group type: COMPARATOR
Intervention: Myoglobin levels at admission
Number of subjects: 33
Study 12760310 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T (TnT) levels at 2 hours
Number of subjects: 33
Study 12760310 — intervention group
Group type: COMPARATOR
Intervention: Creatinine Kinase (CK) levels
Number of subjects: 33
Study 12760310 — intervention group
Group type: EXPERIMENTAL
Intervention: All tests after 4 hours
Number of subjects: 33
Study 10234944 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic antioxidants (dibunol, probucol, emoxipine)
Number of subjects: 202
Study 10234944 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 202
Study 8990830 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0
Study 1862894 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with propofol
Number of subjects: 40
Study 1862894 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and fentanyl (control)
Number of subjects: 40
Study 6192894 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOB (cyclophosphamide on day 1, prednisone on days 1 to 5, vincristine and bleomycin on day 15 of each 21-day cycle)
Number of subjects: 90
Study 6192894 — intervention group
Group type: COMPARATOR
Intervention: COPB (cyclophosphamide, prednisone, vincristine and bleomycin on day 1)
Number of subjects: 90
Study 6192894 — intervention group
Group type: COMPARATOR
Intervention: BCVP (maintenance therapy for responders)
Number of subjects: 90
Study 6192894 — intervention group
Group type: COMPARATOR
Intervention: COPA (maintenance therapy for responders)
Number of subjects: 90
Study 31958178 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with early CNI elimination
Number of subjects: 115
Study 31958178 — intervention group
Group type: COMPARATOR
Intervention: CNI-based immunosuppression
Number of subjects: 115
Study 31958178 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR (1R, 2R, 3R)
Number of subjects: 115
Study 31958178 — intervention group
Group type: EXPERIMENTAL
Intervention: 1R
Number of subjects: 115
Study 31958178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ACR
Number of subjects: 115
Study 30692186 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified method for complete denture fabrication
Number of subjects: 36
Study 30692186 — intervention group
Group type: COMPARATOR
Intervention: Conventional method for complete denture fabrication
Number of subjects: 36
Study 28478716 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian (530 mg) nightly 1 hour before sleep for 4 weeks
Number of subjects: 51
Study 28478716 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly 1 hour before sleep for 4 weeks
Number of subjects: 51
Study 28478716 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 51
Study 28478716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27078988 — intervention group
Group type: EXPERIMENTAL
Intervention: MSBD + CAG
Number of subjects: 46
Study 27078988 — intervention group
Group type: COMPARATOR
Intervention: CAG + placebos
Number of subjects: 46
Study 24722261 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO-2010 (4/24 patients, 17%)
Number of subjects: 32
Study 24722261 — intervention group
Group type: COMPARATOR
Intervention: MDCO-2010 (highest dosage groups)
Number of subjects: 32
Study 22999984 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia group (LMA removal during anesthesia with 2.2% sevoflurane)
Number of subjects: 92
Study 22999984 — intervention group
Group type: COMPARATOR
Intervention: Awake group (LMA removal when patients met recovery criteria)
Number of subjects: 92
Study 22999984 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia group
Number of subjects: 92
Study 22999984 — intervention group
Group type: COMPARATOR
Intervention: Awake group
Number of subjects: 92
Study 19201291 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Rhino tampon
Number of subjects: 13
Study 19201291 — intervention group
Group type: COMPARATOR
Intervention: Rhino Rocket tampon
Number of subjects: 13
Study 18067483 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment twice daily
Number of subjects: 106
Study 18067483 — intervention group
Group type: COMPARATOR
Intervention: Dithranol cream once daily
Number of subjects: 106
Study 15788020 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich liquid supplement (PR; 200 kcal and 20 g protein day(-1))
Number of subjects: 45
Study 15788020 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich liquid supplement (PR; 200 kcal and 20 g protein day(-1)) + nandrolone decanoate injections (PR/N) 25 mg i.m. every third week
Number of subjects: 45
Study 15788020 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 45
Study 11849631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Evra/Evra transdermal patch (3 consecutive 7-day patches for 21 days with 1 patch-free week)
Number of subjects: 3319
Study 11849631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Evra/Evra transdermal patch
Number of subjects: 3319
Study 10450383 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml carbachol intracamerally (carbachol group)
Number of subjects: 51
Study 10450383 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution intracamerally (control group)
Number of subjects: 51
Study 10450383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 7761314 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL reconstruction
Number of subjects: 0
Study 7761314 — intervention group
Group type: COMPARATOR
Intervention: Open ACL reconstruction
Number of subjects: 0
Study 2246784 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video
Number of subjects: 312
Study 2246784 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally involving video
Number of subjects: 312
Study 2246784 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 312
Study 6101459 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg synthetic beta-endorphin
Number of subjects: 14
Study 31511330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/d
Number of subjects: 823
Study 31511330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 823
Study 28840622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis with 8%-12% galangin plus mouth rinsing with sodium bicarbonate
Number of subjects: 60
Study 28840622 — intervention group
Group type: COMPARATOR
Intervention: Mouth rinsing with sodium bicarbonate
Number of subjects: 60
Study 28840622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis plus bicarbonate
Number of subjects: 60
Study 26370380 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with extravirgin olive oil (MedDiet+EVOO)
Number of subjects: 3614
Study 26370380 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with mixed nuts (MedDiet+Nuts)
Number of subjects: 3614
Study 26370380 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 3614
Study 26370380 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet adherence (highest vs lowest quintile)
Number of subjects: 3614
Study 23673286 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (0.4ng/kg)
Number of subjects: 16
Study 23673286 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 16
Study 21175373 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 132
Study 21175373 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin IR 15 mg/day
Number of subjects: 132
Study 19411362 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical vignettes manipulating expected progress and patient adherence to treatment
Number of subjects: 21
Study 19411362 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding guideline variables (short-term progress assessment, current condition, and guideline step)
Number of subjects: 21
Study 17713338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free gum containing 20 mg citric acid and 18.8 mg CPP-ACP
Number of subjects: 10
Study 17713338 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free gum containing 20 mg citric acid alone
Number of subjects: 10
Study 17713338 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free gum not containing CPP-ACP or citric acid
Number of subjects: 10
Study 14960434 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 14962
Study 14960434 — intervention group
Group type: COMPARATOR
Intervention: Non-drinkers
Number of subjects: 14962
Study 11254818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (median prednisolone dose 61 g)
Number of subjects: 367
Study 11254818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 367
Study 9013361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cerebral infarction
Number of subjects: 6
Study 9013361 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls with SAS
Number of subjects: 6
Study 8162731 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 19
Study 8162731 — intervention group
Group type: COMPARATOR
Intervention: Provocholine
Number of subjects: 19
Study 3278494 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol, mean dose 4.8 ± 0.4 mg
Number of subjects: 0
Study 3278494 — intervention group
Group type: COMPARATOR
Intervention: Diazepam, mean dose 12.0 ± 1.0 mg
Number of subjects: 0
Study 3278494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 30758896 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Hz vibration
Number of subjects: 60
Study 30758896 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz vibration
Number of subjects: 60
Study 30758896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 28707325 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp nerve block with 0.25% ropivacaine after intubation
Number of subjects: 44
Study 28707325 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 1 μg/kg just before the scalp incision
Number of subjects: 44
Study 28707325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 26840421 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (therapeutic Qi stimulation)
Number of subjects: 30
Study 26840421 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (needle untouched)
Number of subjects: 30
Study 26840421 — intervention group
Group type: COMPARATOR
Intervention: Null intervention (no needle inserted)
Number of subjects: 30
Study 23144449 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased HCQ dose to achieve target [HCQ] ≥1000 ng/ml (group 2)
Number of subjects: 171
Study 23144449 — intervention group
Group type: COMPARATOR
Intervention: No daily dose change (group 1)
Number of subjects: 171
Study 23144449 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at therapeutic target [HCQ] throughout follow-up
Number of subjects: 171
Study 20617348 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 0
Study 20617348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18827045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 477
Study 18827045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 18827045 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 477
Study 16553240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudine
Number of subjects: 0
Study 14616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 18
Study 14616257 — intervention group
Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 18
Study 11382895 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (4x50 microgram, at 2200, 2300, 2400 and 0100 h)
Number of subjects: 42
Study 11382895 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 42
Study 9178335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (50-150 ng/ml)
Number of subjects: 68
Study 9178335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9178335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 68